Virtual Dialogue 3: Taking Charge of Your Care
Third International Virtual Dialogue The Chondrosarcoma CS Foundation, Inc. held the Third International Forum / Virtual Dialogue featuring a panel of Chondrosarcoma survivors and prominent experts to…
News
Rare Disease Innovation and Data Sharing Accelerated by New RDCA-DAP Program TUCSON, Ariz. and WASHINGTON, September 15, 2021 — The Rare Disease Cures Accelerator-Data and Analytics Platform initiative (RDCA-DAP ®) officially launched its next…
Study Description
Go to Brief Summary:
This phase II trial studies how well atezolizumab works in treating patients with chondrosarcoma or clear cell sarcoma that is newly diagnosed, cannot be removed by surgery (unresectable), or has spread to…
Last Notice Chondrosarcoma CS Foundation, Inc.
Virtual Dialogue 3: Taking Charge of Your Care
Third International Virtual Dialogue (VIA Zoom)
Tuesday, September 14, 2021
7:30PM – 9:00PM (Eastern Standard Time / New York) This Event is Free to…
The Chondrosarcoma Foundation is hosting its first fundraising event to bring awareness to Chondrosarcoma: a rare bone and soft tissue cancer.
Where: The comfort of your own neighborhood!
When: anytime between October 3rd-9th
…
https://www.eventbrite.com/e/steppin-for-a-cause-tickets-166736518415
The Chondrosarcoma CS Foundation, Inc. will host its Third International Forum / Virtual Dialogue featuring a panel of Chondrosarcoma Survivors and prominent experts to examine new technologies, medications, and clinical trials, as well as providing…
Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist For more information: Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human…